Preface |
|
v | |
Contributors |
|
xi | |
|
PART I INTRODUCTION TO SINGLE-DOMAIN ANTIBODIES |
|
|
|
1 Nanobodies: From Serendipitous Discovery of Heavy Chain-Only Antibodies in Camelids to a Wide Range of Useful Applications |
|
|
3 | (16) |
|
|
|
|
|
|
2 Overview, Generation, and Significance of Variable New Antigen Receptors (VNARs) as a Platform for Drug and Diagnostic Development |
|
|
19 | (18) |
|
|
|
|
|
PART II ISOLATION OF SINGLE-DOMAIN ANTIBODIES |
|
|
|
3 Llama DNA Immunization and Isolation of Functional Single-Domain Antibody Binders |
|
|
37 | (34) |
|
|
|
|
|
|
4 Preparation of Immune and Synthetic VNAR Libraries as Sources of High-Affinity Binders |
|
|
71 | (24) |
|
Jahaziel Gasperin-Bulbarela |
|
|
|
|
|
5 Isolation of Single-Domain Antibodies to Transmembrane Proteins Using Magnetized Yeast Cell Targets |
|
|
95 | (26) |
|
|
|
|
6 A Transgenic Heavy Chain IgG Mouse Platform as a Source of High Affinity Fully Human Single-Domain Antibodies for Therapeutic Applications |
|
|
121 | (24) |
|
|
|
|
|
PART III EXPRESSION OF SINGLE-DOMAIN ANTIBODIES |
|
|
|
7 Cytoplasmic Production of Nanobodies and Nanobody-Based Reagents by Co-Expression of Sulfhydryl Oxidase and DsbC Isomerase |
|
|
145 | (14) |
|
|
8 Small-Scale Secretory VHH Expression in Saccharomyces cerevisiae |
|
|
159 | (22) |
|
|
Marga van Hagen-van Setten |
|
|
|
9 Production of Single-Domain Antibodies in Pichia pastoris |
|
|
181 | (24) |
|
|
|
|
|
10 Production of Designer VHH-Based Antibodies in Plants |
|
|
205 | (28) |
|
|
PART IV SINGLE-DOMAIN ANTIBODY ENGINEERING AND CHARACTERIZATION |
|
|
|
11 Assessing the Aggregation Propensity of Single-Domain Antibodies upon Heat-Denaturation Employing the ATm Shift |
|
|
233 | (12) |
|
|
12 Facile Affinity Maturation of Single-Domain Antibodies Using Next-Generation DNA Sequencing |
|
|
245 | (24) |
|
|
|
|
|
|
|
13 Engineering pH-Sensitive Single-Domain Antibodies |
|
|
269 | (30) |
|
|
|
14 Humanization of Camelid Single-Domain Antibodies |
|
|
299 | (14) |
|
|
15 Creation of Multimeric Single-Domain Antibodies Using Bacterial Superglues |
|
|
313 | (14) |
|
|
|
|
16 Introducing Cysteines into Nanobodies for Site-Specific Labeling |
|
|
327 | (18) |
|
|
|
17 Affinity-Guided Site-Selective Labeling of Nanobodies with Aldehyde Handles |
|
|
345 | (12) |
|
|
|
18 Cytoplasmic Expression of Nanobodies with Formylglycine Generating Enzyme Tag and Conversion to a Bio-Orthogonal Aldehyde Group |
|
|
357 | (16) |
|
|
|
|
|
|
|
|
|
19 Site-Specific Fluorescent Labeling, Single-Step Immunocytochemistry, and Delivery of Nanobodies into Living Cells |
|
|
373 | (22) |
|
|
20 Design and Validation of Site-Specifically Labeled Single-Domain Antibody-Based Tracers for in Vivo Fluorescence Imaging and Image-Guided Surgery |
|
|
395 | (14) |
|
|
|
|
21 Design and Preparation of Photobodies: Light-Activated Single-Domain Antibody Fragments |
|
|
409 | (18) |
|
|
|
|
PART V APPLICATIONS OF SINGLE-DOMAIN ANTIBODIES |
|
|
|
22 Visualizing Filoviral Nucleoproteins Using Nanobodies Fused to the Ascorbate Peroxidase Derivatives APEX2 and dEAPX |
|
|
427 | (24) |
|
|
|
23 Development of Glypican-2 Targeting Single-Domain Antibody CART Cells for Neuroblastoma |
|
|
451 | (18) |
|
|
|
24 Single-Domain Antibodies for Intracellular Toxin Neutralization |
|
|
469 | (20) |
|
|
|
25 Generation of Single-Domain Antibody-Based Recombinant Immunotoxins |
|
|
489 | (24) |
|
|
|
26 X-ray Crystal Structure Analysis of VHH-Protein Antigen Complexes |
|
|
513 | (18) |
|
|
|
27 Functionalization of Magnetic Beads with Biotinylated Nanobodies for MALDI-TOF/MS-Based Quantitation of Small Analytes |
|
|
531 | (16) |
|
|
|
Gualberto Gonzalez-Sapienza |
|
|
28 Nanobody-Based Assays for the Detection of Environmental and Agricultural Contaminants |
|
|
547 | (8) |
|
|
|
29 Peptide-Tag Specific Nanobodies for Studying Proteins in Live Cells |
|
|
555 | (26) |
|
|
|
30 Nanobody-Based GFP Traps to Study Protein Localization and Function in Developmental Biology |
|
|
581 | (14) |
|
|
|
|
|
31 Cytogenetic Activation of Intracellular Nanobodies |
|
|
595 | |
|
|
Correction to: Cytogenetic Activation of Intracellular Nanobodies |
|
1 | (606) |
Index |
|
607 | |